How is sensitive data protected?

All documents are encrypted with AES-256-GCM at rest and TLS 1.3 in transit. A GDPR anonymization layer removes PII before any AI processing. Your data never leaves our SOC 2 certified infrastructure.

How long does integration take?

Less than 30 minutes. Upload documents directly, connect via OAuth for Slack, or use our REST API for bulk processing.

How does outcome tracking work?

Outcomes are detected automatically from follow-up documents, Slack messages, and web intelligence. You confirm with one click. Each reported outcome makes your future analyses more accurate.

How is Decision Intel different from ChatGPT?

ChatGPT gives one opinion from one model. Decision Intel uses 3 independent judges for noise measurement, a 20×20 bias interaction matrix for compound scoring, 31 domain-specific biases, and an outcome flywheel that gets smarter with every decision.

All case studies

FailureHealthcare2021

Biogen

Biogen Aduhelm Approval Controversy

Estimated impact: $11B market cap loss when CMS restricted coverage; institutional credibility damage

F30

Decision Quality Index

Critical — 5 biases detected, 2 toxic combinations

The FDA approved Biogen's Alzheimer's drug Aduhelm via accelerated approval despite an advisory committee voting nearly unanimously against it. The $56,000/year drug showed no clear clinical benefit. Three advisory committee members resigned in protest. CMS later restricted coverage.

Decision context

Whether the FDA should have approved a drug that failed two Phase III trials and whose advisory committee voted 10-0 (with 1 uncertain) against approval.

Deep hindsight-stripped analysis coming soon. This case is part of our ongoing backfill to reconstruct what the platform would have flagged at decision time. The summary and bias profile below are drawn from primary sources.

Biases present in the decision

Authority BiasConfirmation Bias★ Optimism BiasAnchoring BiasGroupthink

3D Decision Knowledge Graph

Biogen — 5 biases, 2 toxic combinations

Drag to rotate · Scroll to zoom · Click to explore

Decision

Critical

High

Medium

Toxic

Bias Intensity Profile

Severity × confidence across 5 detected biases

Toxic combinations

Optimism Trap
Yes Committee

Reference class base rates

Across all 146 curated case studies in our library:

90%

base failure rate

10%

base success rate

Lessons learned

Optimism bias in Alzheimer's research created pressure to approve any drug showing a biomarker effect regardless of clinical outcomes
Overriding an advisory committee's near-unanimous rejection damages the credibility of the regulatory process
Accelerated approval based on surrogate endpoints (amyloid reduction) when clinical benefit is unproven sets a dangerous precedent

Source: FDA Peripheral and Central Nervous System Drugs Advisory Committee meeting transcript (2020); STAT News investigation (2021) (FDA Action)

Pilot slots available

See what we'd flag in your next strategic memo.

Upload a strategic memo or board deck. Get the same bias audit you just saw for Biogen, on your own high-stakes call, in under 60 seconds.

Try the Demo — Free Request a Pilot

Or leave your email, we'll run a strategic memo of your choosing and send the readout within a business day.

Ready to audit your own memo right now? Create a free account →

Related cases in Healthcare

Catastrophic failure2004

Merck

Vioxx Withdrawal

Catastrophic failure1996

Purdue Pharma

Purdue Pharma OxyContin Marketing

Failure1970

Johnson & Johnson

Johnson & Johnson Talc Powder Litigation

Lessons learned

Optimism bias in Alzheimer's research created pressure to approve any drug showing a biomarker effect regardless of clinical outcomes

Overriding an advisory committee's near-unanimous rejection damages the credibility of the regulatory process

Accelerated approval based on surrogate endpoints (amyloid reduction) when clinical benefit is unproven sets a dangerous precedent